Resultados da pesquisa - Portal para modelos de dados médicos (portal MDM)

Bioavailability and Pharmacokinetics of Testosterone with/without Dutasteride - 106218 - Part 2 - Treatment Period Day 15 - Investigational Product/Treatment Confirmation

- 04/03/2019 - 1 Formulário, 3 Grupos de itens, 7 Elementos de dados, 1 Idioma

Grupos de itens: Administrative documentation, Experimental drug, Therapeutic Procedure, Confirmation

Study ID: 106218 Clinical Study ID: TDC106218 Study Title: Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: testosterone Trade Name: Andropatch,Androderm Study Indication: Hypogonadism, Male

Pharmacokinetics of an oral contraceptive co-administered with Albiglutide in women - 107032 - Period 1 Day 1 (Visit 80)

- 21/12/2018 - 1 Formulário, 9 Grupos de itens, 49 Elementos de dados, 1 Idioma

Grupos de itens: Administrative data, Admission Criteria, Study Drug Administration, Laboratory Test - Hematology, Laboratory Test - Chemistry, Laboratory Test - UA / UDS / Urine HCG / Urine Chemistry, Vital Signs, Pharmacodynamic Blood Collection, Pharmacodynamic Blood Collection

Study ID: 107032 Clinical Study ID: GLP107032 Study Title: An open-label study to evaluate the pharmacokinetics of an oral contraceptive containing Norethindrone and Ethinyl Estradiol when co-administered with GSK716155 in healthy adult female subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01077505 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: albiglutide Trade Name: Tanzeum,Eperzan Study Indication: Diabetes Mellitus, Type 2

The Effect of Albiglutide on Cardiac Repolarisation Compared with Placebo 107085 - Day 3: Vital Signs

- 15/11/2018 - 1 Formulário, 3 Grupos de itens, 18 Elementos de dados, 1 Idioma

Grupos de itens: Administrative data, Admission Criteria, Vital Signs

Study ID: 107085 Clinical Study ID: GLP107085 Study Title: A Randomized, Double-blind, Parallel, Nested Crossover Study to Investigate the Effect of Albiglutide on Cardiac Repolarization (corrected QT Interval) Compared With Placebo in Healthy Male and Female Subjects: A Thorough ECG Study Employing Placebo, Albiglutide, and a Positive Control (Moxifloxacin) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01406262 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: albiglutide Trade Name: Tanzeum,Eperzan Study Indication: Diabetes Mellitus, Type 2

The Effect of Albiglutide on Cardiac Repolarisation Compared with Placebo 107085 - Screening Visit: Eligibility and Admission

- 14/11/2018 - 1 Formulário, 3 Grupos de itens, 14 Elementos de dados, 1 Idioma

Grupos de itens: Administrative data, Informed Consent, Admission Criteria

Study ID: 107085 Clinical Study ID: GLP107085 Study Title: A Randomized, Double-blind, Parallel, Nested Crossover Study to Investigate the Effect of Albiglutide on Cardiac Repolarization (corrected QT Interval) Compared With Placebo in Healthy Male and Female Subjects: A Thorough ECG Study Employing Placebo, Albiglutide, and a Positive Control (Moxifloxacin) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01406262 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: albiglutide Trade Name: Tanzeum,Eperzan Study Indication: Diabetes Mellitus, Type 2

Evaluation of LAMICTAL for Add-on Treatment of Partial Seizures in Pediatric Patients 105-040 - Admission Criteria/ Demography - Screen

- 08/10/2018 - 1 Formulário, 3 Grupos de itens, 11 Elementos de dados, 1 Idioma

Grupos de itens: Administrative documentation, Patient Admission criteria, Demography

Study ID: 105-040 Clinical Study ID: 105-040 Study Title: A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Design Evaluation of LAMICTAL for Add-on Treatment of Partial Seizures in Pediatric Patients Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: lamotrigine Trade Name: lamictal Study Indication: Epilepsy, Partial

Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphomas NCT00996593 - Patient enrollment

- 21/07/2018 - 1 Formulário, 6 Grupos de itens, 56 Elementos de dados, 1 Idioma

Grupos de itens: Demographics, Inclusion Criteria Histology, Inclusion Criteria, Exclusion Criteria, Administrative, For Coulter use only

Study ID: 104507 Clinical Study ID: BEX104507 Study Title: Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphoma Patients who have Previously Received Rituximab Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996593 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Patient Enrollment

- 10/07/2018 - 1 Formulário, 11 Grupos de itens, 39 Elementos de dados, 1 Idioma

Grupos de itens: Demographics, Lymphoid Neoplasms; Inclusion Criteria, CD20 antigen; Inclusion Criteria, Prior chemotherapy; Inclusion Criteria, Karnofsky Performance Status; Survival time, Anticipated; Inclusion Criteria, ANC; Platelet Count; Inclusion Criteria, Renal function; Hepatic function; Inclusion Criteria, Bi-dimensionally measured disease; Inclusion Criteria, Age; Inclusion Criteria, Informed Consent; Inclusion Criteria, Exclusion criteria

Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

CEC - Hospitalisation for heart failure GSK study Chronic Coronary Heart Disease NCT00799903

- 11/01/2018 - 1 Formulário, 3 Grupos de itens, 18 Elementos de dados, 1 Idioma

Grupos de itens: CEC - Hospitalisation for heart failure, Hospitalisation for heart failure - CEC Section, CEC Status

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: CEC - Hospitalisation for heart failure Repeating form (Scheduled visits)

Endpoint Hospitalisation for unstable angina GSK study Chronic Coronary Heart Disease NCT00799903

- 09/01/2018 - 1 Formulário, 3 Grupos de itens, 40 Elementos de dados, 1 Idioma

Grupos de itens: Investigator section, CEC Section, CEC Status

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Endpoint Hospitalisation for unstable angina - Repeating form (Scheduled visits)

CEC - Hospitalisation for unstable angina GSK study Chronic Coronary Heart Disease NCT00799903

- 04/01/2018 - 1 Formulário, 3 Grupos de itens, 21 Elementos de dados, 1 Idioma

Grupos de itens: Hospitalisation for unstable angina, Hospitalisation for unstable angina - CEC Section, CEC Status

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: CEC Hospitalisation for unstable angina Repeating form (Scheduled visits)

Hospitalisation Repeating form GSK study Chronic Coronary Heart Disease NCT00799903

- 01/01/2018 - 1 Formulário, 2 Grupos de itens, 9 Elementos de dados, 1 Idioma

Grupos de itens: Hospitalisation, Discharge diagnoses

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Hospitalisation - Repeating form (Scheduled visits)

KBV Referral to hospital Template 2 - KBV Referral to hospital Template 2b

- 05/09/2017 - 3 Formulários, 4 Grupos de itens, 18 Elementos de dados, 1 Idioma

Grupos de itens: Header, Referral to hospital, Footer, Further information

Muster 2 - Verordnung von Krankenhausbehandlung (Freigabe: 01.09.2014) - 10.2014, Formulare für die vertragsärztliche Versorgung Freigabe durch Dezernat 4 - Ärztliche Leistungen und Versorgungsstruktur Geschäftsbereich Sicherstellung und Versorgungsstruktur Abteilung Sicherstellung Herbert-Lewin-Platz 2 10623 Berlin Tel: + 49 (0) 30 - 4005 -1418 Fax: + 49 (0) 30 - 4005 - 271418 Email: SJohn@KBV.de Web: www.kbv.de Quelle: http://www.kbv.de/html/formulare.php Forms for contract medical care Released by Department 4 - Medical treatment and structure of supply, division ensurance and structure of supply, department ensurance Herbert-Lewin-Platz 2 10623 Berlin Tel: + 49 (0) 30 - 4005 -1418 Fax: + 49 (0) 30 - 4005 - 271418 Email: SJohn@KBV.de Web: www.kbv.de Source: http://www.kbv.de/html/formulare.php

KBV Referral to hospital Template 2c

4 Grupos de itens 18 Elementos de dados

KBV Referral to hospital Template 2a

4 Grupos de itens 17 Elementos de dados

Palavras-chave

Índice

Modelos de dados selecionados